Onyx Scientific reported a 45% growth in its solid formulation-related revenues this year, driven by early stage drug development projects. The company’s alliance with Molecular Profiles has also contributed to growth, with increased activity in the biotechnology and early stage clinical sector.
Denise Bowser, commercial director at Onyx Scientific, said, “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to cut lead times for clients and ensure processes are scalable. As many drugs are formulated in solid dosage form, the need to understand, control and characterize the individual forms of a substance, in particular the polymorphic form is vital. This is why we feel we have seen such an increased demand.”
Onyx Scientific, a contract research and manufacturing organization, has MHRA and FDA facilities in the UK and India, and provides medicinal chemistry and preclinical through Phase I-III, scaling up to large scale commercial API production.